Spots Global Cancer Trial Database for synovial sarcoma
Every month we try and update this database with for synovial sarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy | NCT01674101 | Osteosarcoma Ewing's Sarcoma Rhabdomyosarcom... Synovial Sarcom... Malignant Perip... Malignant Fibro... Chondrosarcoma ... | Endurance Strengthening Stretching Home exercise p... | 6 Years - 30 Years | St. Jude Children's Research Hospital | |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | NCT03638206 | B-cell Acute Ly... Lymphoma Myeloid Leukemi... Multiple Myelom... Hepatoma Gastric Cancer Pancreatic Canc... Mesothelioma Colorectal Canc... Esophagus Cance... Lung Cancer Glioma Melanoma Synovial Sarcom... Ovarian Cancer Renal Carcinoma | CAR-T cell immu... | 4 Years - 70 Years | Shenzhen BinDeBio Ltd. | |
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| Sorafenib and Dacarbazine in Soft Tissue Sarcoma | NCT00837148 | Sarcoma Synovial Sarcom... Leiomyosarcoma Malignant Perip... | Sorafenib and D... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma | NCT03250325 | Synovial Sarcom... | TBI-1301 Cyclophosphamid... | 18 Years - | Takara Bio Inc. | |
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | NCT05492682 | Melanoma (Skin) Triple-Negative... Non-Small Cell ... Synovial Sarcom... Myxoid Liposarc... Colorectal Canc... | PeptiCRAd-1 Cyclophosphamid... Pembrolizumab | 18 Years - | Valo Therapeutics Oy | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients | NCT04008238 | Soft Tissue Sar... Undifferentiate... Epithelioid Sar... Solitary Fibrou... Hemangioendothe... Desmoplastic Ro... Synovial Sarcom... | Trabectedin | 18 Years - | Institut Bergonié | |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | NCT03016819 | Alveolar Soft P... Leiomyosarcoma Synovial Sarcom... Soft-Tissue Sar... | AL3818 Dacarbazine AL3818 or place... | 18 Years - | Advenchen Laboratories, LLC | |
| A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | NCT02601937 | Rhabdoid Tumors INI1-negative T... Synovial Sarcom... Malignant Rhabd... | Tazemetostat | 6 Months - 17 Years | Epizyme, Inc. | |
| Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | NCT00297258 | Sarcoma, Soft T... | pazopanib | 21 Years - | GlaxoSmithKline | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | NCT01241162 | Neuroblastoma Ewings Sarcoma Osteogenic Sarc... Rhabdomyosarcom... Synovial Sarcom... | Autologous dend... | 1 Year - 24 Years | University of Louisville | |
| Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | NCT02869217 | NY-ESO-1 Expres... Synovial Sarcom... Melanoma Esophageal Canc... Ovarian Cancer Lung Cancer Bladder Cancer Liver Cancer | Cyclophosphamid... TBI-1301 Fludarabine | 16 Years - | University Health Network, Toronto | |
| Investigator Initiated Phase 1 Study of TBI-1301 | NCT02366546 | Solid Tumors | TBI-1301 Cyclophosphamid... Fludarabine | 20 Years - | Mie University | |
| Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | NCT00949325 | Sarcoma | temsirolimus pl... | 1 Year - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma | NCT01883518 | Sarcoma Neoplasms, Conn... | Autologous dend... | 18 Years - | N.N. Petrov National Medical Research Center of Oncology | |
| Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | NCT04537715 | All Malignancie... Advanced Malign... Hematologic Mal... Solid Tumor Follicular Lymp... Non-Hodgkin Lym... Diffuse Large B... Epithelioid Sar... Synovial Sarcom... Renal Medullary... Mesothelioma Rhabdoid Tumor | Tazemetostat Itraconazole Tazemetostat Rifampin | 18 Years - | Ipsen | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | NCT04906876 | Sarcoma Soft Tissue Sar... Metastatic Sarc... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma | Gemcitabine Docetaxel 9-ING-41 | 10 Years - | Brown University | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | NCT05116800 | Soft Tissue Sar... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma Osteosarcoma Ewing Sarcoma o... | Gemcitabine 9-ING-41 Docetaxel | 10 Years - | Brown University | |
| Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy | NCT01674101 | Osteosarcoma Ewing's Sarcoma Rhabdomyosarcom... Synovial Sarcom... Malignant Perip... Malignant Fibro... Chondrosarcoma ... | Endurance Strengthening Stretching Home exercise p... | 6 Years - 30 Years | St. Jude Children's Research Hospital | |
| Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a | NCT03697824 | Neoplasms | GSK3377794 Pembrolizumab Fludarabine Cyclophosphamid... | 10 Years - | GlaxoSmithKline | |
| Investigator Initiated Phase 1 Study of TBI-1301 | NCT02366546 | Solid Tumors | TBI-1301 Cyclophosphamid... Fludarabine | 20 Years - | Mie University | |
| A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | NCT05355753 | Synovial Sarcom... Soft Tissue Sar... | CFT8634 | 12 Years - | C4 Therapeutics, Inc. | |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | NCT04420975 | Leiomyosarcoma Malignant Perip... Myxofibrosarcom... Pleomorphic Rha... Resectable Dedi... Resectable Soft... Resectable Undi... Soft Tissue Fib... Spindle Cell Sa... Stage I Retrope... Stage I Soft Ti... Stage IA Retrop... Stage IA Soft T... Stage IB Retrop... Stage IB Soft T... Stage II Retrop... Stage II Soft T... Stage III Retro... Stage III Soft ... Stage IIIA Retr... Stage IIIA Soft... Stage IIIB Retr... Stage IIIB Soft... Storiform-Pleom... Synovial Sarcom... Undifferentiate... Undifferentiate... Undifferentiate... Undifferentiate... Undifferentiate... | Definitive Surg... Nanoplexed Poly... Nivolumab Radiation Thera... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016 | NCT03833037 | Soft Tissue Sar... | Soft tissue sar... | 10 Years - 100 Years | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| Detection of Circulating Tumor Cells in Patients With Sarcomas | NCT02983539 | Leiomyosarcoma Pleomorphic Lip... Synovial Sarcom... Liposarcoma | 18 Years - 70 Years | AC Camargo Cancer Center | ||
| Bevacizumab and Radiation Therapy for Sarcomas | NCT00356031 | Soft Tissue Sar... Fibrous Histioc... Liposarcoma Leiomyosarcoma Fibrosarcoma Synovial Sarcom... | Bevacizumab Radiation Thera... Surgery | 18 Years - | Massachusetts General Hospital | |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | NCT04995003 | Sarcoma HER-2 Protein O... Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma Synovial Sarcom... Soft Tissue Sar... Undifferentiate... | T cells or CAR ... Pembrolizumab I... Nivolumab Injec... | 1 Year - 25 Years | Baylor College of Medicine | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT04483778 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma Melanoma | second generati... second generati... Pembrolizumab | 0 Years - 26 Years | Seattle Children's Hospital | |
| Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases | NCT02181829 | Synovial Sarcom... Single or Multi... | Whole Lung IMRT | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin | NCT03773510 | Leiomyosarcoma Liposarcoma Synovial Sarcom... | Trabectedin dis... Trabectedin con... | 18 Years - | Italian Sarcoma Group | |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) | NCT03520959 | Synovial Sarcom... Cancer Soft Tissue Sar... Sarcoma Metastatic Sarc... | LV305 G305 LV305-matching ... G305-matching p... | 12 Years - | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | NCT04995003 | Sarcoma HER-2 Protein O... Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma Synovial Sarcom... Soft Tissue Sar... Undifferentiate... | T cells or CAR ... Pembrolizumab I... Nivolumab Injec... | 1 Year - 25 Years | Baylor College of Medicine | |
| Blood and Tissue Study of Patients in NIH Protocol 08-C-0800 | NCT00923325 | Sarcomas | 2 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | NCT03016819 | Alveolar Soft P... Leiomyosarcoma Synovial Sarcom... Soft-Tissue Sar... | AL3818 Dacarbazine AL3818 or place... | 18 Years - | Advenchen Laboratories, LLC | |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | NCT02584309 | Sarcoma, Soft T... Soft Tissue Sar... Undifferentiate... Leiomyosarcoma Liposarcoma Synovial Sarcom... Myxofibrosarcom... Angiosarcoma Fibrosarcoma Malignant Perip... Epithelioid Sar... | Dexrazoxane Doxorubicin | 18 Years - | Washington University School of Medicine | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Detection of Circulating Tumor Cells in Patients With Sarcomas | NCT02983539 | Leiomyosarcoma Pleomorphic Lip... Synovial Sarcom... Liposarcoma | 18 Years - 70 Years | AC Camargo Cancer Center | ||
| FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | NCT04965753 | Advanced Synovi... | FHD-609 | 16 Years - | Foghorn Therapeutics Inc. | |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | NCT03604783 | Advanced Solid ... Sarcoma Ewing Sarcoma Dedifferentiate... Synovial Sarcom... | TP-1287 | 12 Years - | Sumitomo Pharma America, Inc. | |
| Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | NCT00949325 | Sarcoma | temsirolimus pl... | 1 Year - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | NCT03604783 | Advanced Solid ... Sarcoma Ewing Sarcoma Dedifferentiate... Synovial Sarcom... | TP-1287 | 12 Years - | Sumitomo Pharma America, Inc. | |
| Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma | NCT00876031 | Soft Tissue Sar... | trofosfamide, i... | 6 Months - 21 Years | University Hospital Tuebingen | |
| Synovial Sarcoma Registry / Biospecimen Repository | NCT05910307 | Synovial Sarcom... | - | Children's Hospital of Philadelphia | ||
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT03618381 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma | second generati... second generati... | 1 Year - 30 Years | Seattle Children's Hospital | |
| Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | NCT01957709 | Myxoid Liposarc... Round Cell Lipo... Synovial Sarcom... | Laboratory Biom... Recombinant Int... | 18 Years - | Fred Hutchinson Cancer Center | |
| DHEA in Synovial Sarcoma Patients | NCT02683148 | Synovial Sarcom... Sarcoma, Synovi... | DHEA FACT-67 validat... | 16 Years - | Washington University School of Medicine | |
| Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma | NCT03250325 | Synovial Sarcom... | TBI-1301 Cyclophosphamid... | 18 Years - | Takara Bio Inc. | |
| Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases | NCT02181829 | Synovial Sarcom... Single or Multi... | Whole Lung IMRT | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) | NCT00543712 | Chondrosarcoma | PRO95780 | 18 Years - | Genentech, Inc. | |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | NCT04145700 | Synovial Sarcom... | Ramucirumab Gemcitabine Docetaxel | 12 Months - 29 Years | Eli Lilly and Company | |
| A Study to Assess the Long-term Safety of Tazemetostat | NCT02875548 | Diffuse Large B... Follicular Lymp... Synovial Sarcom... Epitheliod Sarc... Mesothelioma Advanced Solid ... Renal Medullary... Non-Hodgkin Lym... | Tazemetostat | 18 Years - | Ipsen | |
| Blood and Tissue Study of Patients in NIH Protocol 08-C-0800 | NCT00923325 | Sarcomas | 2 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | NCT00297258 | Sarcoma, Soft T... | pazopanib | 21 Years - | GlaxoSmithKline | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
